Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Mai 2011 08:30 ET | Quelle: Semafore Pharmaceuticals

Semafore Pharmaceuticals to Present SF1126 Clinical Data at ASCO Annual Meeting

INDIANAPOLIS, May 26, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced that Phase 1 clinical data for SF1126 will be presented at the 47th Annual Meeting of the American Society of...
05. April 2011 13:00 ET | Quelle: Semafore Pharmaceuticals

Semafore Pharmaceuticals Reports New Preclinical Data for Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at AACR

INDIANAPOLIS, April 5, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced encouraging preclinical results for its lead product candidate, SF1126, in certain B-cell malignancies. The...
09. März 2011 07:30 ET | Quelle: Semafore Pharmaceuticals

Semafore Pharmaceuticals Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 AACR Annual Meeting

INDIANAPOLIS, March 9, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals announced today that preclinical data in B-cell malignancies for the company's lead product candidate SF1126 will be presented...